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MaCarotid intima-media thickness (CIMT) has been shown to predict cardiovascular (CV) risk in multiple large studies.
Careful evaluation of CIMT studies reveals discrepancies in the comprehensiveness with which CIMT is assessed—the
number of carotid segments evaluated (common carotid artery [CCA], internal carotid artery [ICA], or the carotid bulb),
the type of measurements made (mean or maximum of single measurements, mean of the mean, or mean of the
maximum for multiple measurements), the number of imaging angles used, whether plaques were included in the intima-
media thickness (IMT) measurement, the report of adjusted or unadjusted models, risk association versus risk prediction,
and the arbitrary cutoff points for CIMT and for plaque to predict risk. Measuring the far wall of the CCA was shown to be
the least variable method for assessing IMT. However, meta-analyses suggest that CCA-IMT alone only minimally
improves predictive power beyond traditional risk factors, whereas inclusion of the carotid bulb and ICA-IMT improves
prediction of both cardiac risk and stroke risk. Carotid plaque appears to be a more powerful predictor of CV risk
compared with CIMT alone. Quantitative measures of plaques such as plaque number, plaque thickness, plaque area, and
3-dimensional assessment of plaque volume appear to be progressively more sensitive in predicting CV risk than mere
assessment of plaque presence. Limited data show that plaque characteristics including plaque vascularity may improve
CV disease risk stratiﬁcation further. IMT measurement at the CCA, carotid bulb, and ICA that allows inclusion of plaque in
the IMT measurement or CCA-IMT measurement along with plaque assessment in all carotid segments is emerging as the
focus of carotid artery ultrasound imaging for CV risk prediction. (J Am Coll Cardiol Img 2014;7:1025–38) © 2014 by the
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with coronary artery calcium (CAC) score a class IIa
recommendation for cardiovascular (CV) risk assess-
ment in asymptomatic adults at intermediate risk of
cardiovascular disease (CVD) (1). In addition, con-
sensus documents from the national societies (2) and
from the American Society of Echocardiography have
simpliﬁed intima-media thickness (IMT) and plaque
assessment methodology (3). Dedicated ultrasound
systems for IMT assessment now incorporate IMT
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plaque assessment a usefulmethod for CVD risk reclas-
siﬁcation in clinical practice (4). Nonetheless, most in-
surers consider CIMT and plaque assessment as
investigational and the data to be insufﬁcient and con-
tradictory to justify reimbursement of CIMT for CV riskassessment (5). This is similar to assessment for CAC,
which is considered investigational by insurers (6).
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ABBR EV I A T I ON S
AND ACRONYMS
CAC = coronary artery calcium
CCA = common carotid artery
CHD = coronary heart disease
CIMT = cardiac intima-media
thickness
CV = cardiovascular
CVD = cardiovascular disease
3D = 3-dimensional
FRS = Framingham Risk Score
HR = hazard ratio
ICA = internal carotid artery
IMT = intima-media thickness
MI = myocardial infarction
NRI = Net Reclassiﬁcation
Index
TRF = traditional risk factor
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1026clinical practice for prediction of CV events
(7). This article reviews studies that evaluated
CIMT for CV risk stratiﬁcation and risk predic-
tion and discusses methodological variability
that accounts for differences in ﬁndings
among studies that has caused confusion
about the role of IMT in CV risk prediction.
The article summarizes studies using CIMT
and plaque in CVD risk association or predic-
tion and discusses the emerging role of carotid
plaque as a better marker of CVD risk than
CIMT.
CIMT MEASUREMENT
CIMT is measured between the intimal-
luminal and the medial-adventitial inter-
faces of the carotid artery wall represented as
a double-line density on an ultrasound image
(Figure 1). The accuracy of the common ca-rotid artery (CCA) far wall IMT measurement was
validated against histological specimens (8) as rep-
resenting the true biological thickness of the vessel
wall, whereas the near-wall IMT measurement was
shown to have a systematic measurement error
because of the echogenicity of the adventitial layer
masking the adventitial-medial boundary (9,10) as
well as being affected by gain settings (10). The
annual changes in IMT are small, and the differences
between 25th and 75th percentiles are <1 mm, and,
therefore, a high degree of precision is required in
CIMT measurement. With sonographer training and
strict adherence to quality control of IMT scanning
protocol including the angles at which CIMT mea-
surements are made, CIMT offers good interscan and
interobserver and intraobserver reproducibility with
an intraclass correlation coefﬁcient >0.90 (11), indi-
cating good test characteristics.
The development of automated edge-tracking soft-
ware, which obviated the need to perform manual
measurements, further improved the reproducibility
of CIMT measurements (12).
CIMT ASSESSMENT IN CLINICAL STUDIES OF
CVD RISK PREDICTION
The carotid artery includes 4 segments, beginningwith
the CCA. This gives rise to the carotid bulb from which
arise the external carotid artery and the internal ca-
rotid artery (ICA) (Figure 2). Large clinical studies that
measured CIMT to determine its value in predicting
incident CVD are listed in Table 1. These CIMT studies
varied in the comprehensivenesswithwhich CIMTwas
assessed. Some imaged only 1 side of the neck,whereas
others imaged bilaterally (Table 1). Some includedimaging of a single segment (13); others imaged mul-
tiple segments (14–16). Some studies imaged the far
wall of multiple segments (17), whereas others imaged
both near and far walls (4,18,19). Far wall measure-
ments of the CCA alone have been favored because the
CCA is perpendicular to the ultrasound beam, easily
assessable, and reproducible (8–10), whereas the ca-
rotid bulb and ICA lie at an oblique angle and are more
difﬁcult to image (12). Studies also differed in the type
of IMT measurements made (mean or maximum for
single measurements, mean of the mean, or mean of
the maximum for multiple measurements), varying
deﬁnition of plaque, whether plaques were included
in the IMT measurements, and the different arbi-
trary cutoff points for CIMT to predict risk. Because
of the focal nature of the atherosclerotic process
(Figures 2 and 3A), IMT measurements at 1 site can be
very different from those taken at another site (14);
hence, measuring CIMT from a single site can lower
the sensitivity of detecting atherosclerotic changes.
Other differences in imaging protocol include the
angle from which CIMT is assessed. Some studies
imaged only from a single angle (13,20), whereas others
imaged frommultiple angles (17,18,21). Imaging from a
single angle does not completely evaluate the carotid
artery in 3 dimensions. Atherosclerosis tends to form
at the carotid bulb, particularly toward the outer
wall where the shear stresses are low and oscillations
in shear stresses are high (22). Extensive ultrasound
protocols are required to fully evaluate the degree of
atherosclerotic burden and observe a treatment effect
(23). The phase of the cardiac cycle (end-systole vs.
end-diastole) when CIMT is measured also differs
among studies. Because of systolic lumen diameter
expansion that leads to thinning of CIMT during sys-
tole, CIMT values obtained from end-systole are lower
than those obtained in end-diastole (24).
The Kuoppio Ischaemic Heart Disease study was
the ﬁrst study to demonstrate an association of CIMT
with future coronary events. In this study, every
0.1-mm increment of IMT was associated with an 11%
increased risk of myocardial infarction (MI) during
follow-up (25). Subsequently, several other large
clinical studies, including the ARIC (Atherosclerosis
Risk in Communities) study (17), the CHS (Cardio-
vascular Health Study) (26), the CAPS (Carotid
Atherosclerosis Progression Study) (27), the MDCS
(Malmo Diet and Cancer Study) (28), and the Rotter-
dam Study (29), all showed that CIMT can be used to
assess incident CVD risk. Plaque presence seemed to
have a more profound effect on improving risk pre-
diction in women than in men.
Studies that evaluated whether CIMT provided
additional prognostic information over and above
FIGURE 1 Measurement of CCA-IMT
Longitudinal ultrasound images of the common carotid artery are shown for a 57-year-old
Caucasian woman with a Framingham Risk Score (FRS) of 1% and with normal carotid
intima-media thickness (<25th percentile) (A), and for a 58-year-old Caucasian man with a
history of familial hypercholesterolemia and an FRS of 8% (B). There is diffuse increased
common carotid artery intima-media thickness (>75th percentile) as well as a plaque in the
near wall of R bulb (not shown). Per ARIC study data, adding cardiac intima-media
thickness adds to the area under the curve over and above the FRS and plaque presence in
males. Hence, in this patient, both plaque and CIMT should be reported.
FIGURE 2 Where Should IMT Be Measured?
The far wall of common carotid artery intima-media thickness (CCA-IMT) corresponds most
closely to histological measures and ismost reproducible. (A) Longitudinal ultrasound image
of the CCA, carotid bulb, and internal carotid artery (ICA) is shown for a 50-year-old female
patientwith a FraminghamRisk Score of 1%andnormal CCA-IMT. (B)Bulb and ICA are shown
in the same patient. There is a plaque in the nearwall of the bulb and a diffuse increase in IMT
at the far wall of the bulb and ICA. If far-wall CCA-IMT is measured and reported, the patient
will be deemed low risk. If plaque is deﬁned as focal protrusion with 1.5-mm thickness, the
maximal near wall of the bulb IMT (1.2mm) andmaximal far wall of the ICA-IMT (1.15mm) do
not meet criteria. This patient will therefore be reported as low risk based on the American
Society of Echocardiography consensus statement. Meta-analysis of studies that only
measured CCA-IMT showed no incremental value over the FRS. This example suggests that
assessment of IMT should be performed at the CCA, bulb, and ICA in select patients.
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1027Framingham risk score (FRS) have been largely
negative. In the MESA (Multi-Ethnic Study of Athero-
sclerosis), CCA-IMT did not predict either coronary
artery disease or stroke risk after adjusting for the FRS
(area under the curve of 0.78 for risk factors plus
CIMT vs. 0.77 for risk factors alone in both models)
(30). Another study found the area under the curve
of 0.69 for CIMT and FRS versus 0.66 for FRS
(31). The CAPS showed that even though CIMT was
signiﬁcantly and independently predictive of CV
events, when added to the FRS and the European car-
diovascular disease risk assessment model systemic
coronary risk evaluation (SCORE) models, it did not
consistently improve the risk classiﬁcation of in-
dividuals (27). A review of the CIMT studies by Simon
et al. (32) shows that in some studies, CIMT added little
to the coronary heart disease (CHD) prediction by risk
factors, as judged by c-statistic and receiver-operating
characteristic curve analysis and that the CHD predic-
tion by CIMT was inferior to that by carotid plaque.
Meta-analyses of CIMT studies have also yielded con-
tradictory results. The ﬁrst meta-analysis that
included major clinical studies with CIMT assessment
of single or multiple carotid segments showed that for
every 0.1-mm increase in CIMT, the future risk of
myocardial infarction (MI) increases by 10% to 15%
(33). A second meta-analysis that evaluated CCA-IMT
alone and excluded CCA or bulb IMT or plaques in
45,828 patients from 14 population-based studies
showed that the addition of CIMT does not add clini-
cally meaningful information to the standard predic-
tion modalities (34,35). The Net Reclassiﬁcation Index
(NRI) with the addition of CCA-IMT was only 0.8% for
the overall cohort and 3.6% for those at intermediate
risk. The NRI examines the net effect of adding a
biomarker to the risk-prediction model, and the clin-
ical NRI is the NRI in intermediate-risk patients only.
This meta-analysis (34) limited to the evaluation of
predictive value of CCA IMT alone was the basis for the
recent recommendation of downgrading of CIMT test
by the 2013 ACC/AHA prevention guidelines (7). Both
meta-analyses (33,34) noted a signiﬁcant variability in
the CIMT methodologies and in reporting of mean or
maximal CIMT of single or multiple segments, making
it difﬁcult to compare studies or to combine the results
from different studies. The ﬁndings of this meta-
analysis are in contrast to the ﬁndings of the ARIC
study, which found no signiﬁcant difference in CHD
risk prediction when CCA-IMT alone was added to
plaque and traditional risk factors (TRFs) versus the
mean combined IMT of all carotid segments added to
plaque and TRFs (36). These differences can partly be
explained by the fact that in the ARIC study, ICA IMT
was only measurable in 43% of study subjects (17).Hence, in majority of subjects, combined IMT essen-
tially represented CCA and bulb IMT, and plaque can be
a representative of bulb IMT because majority of pla-
ques form at the bulb. More recent studies, with better
TABLE 1 CIMT as Prognostic Indicator of Cardiovascular Events
Study (Ref. #)
Sample Size,
No. (% Women)
Age of
Subjects, yrs Follow-Up Carotid Ultrasound Parameters Plaque Endpoints CIMT, RR (95% CI)
KIHD (25) 1,257 (0) 42–60 yrs 1 month to 2.5 yrs CCA-IMT, mean of maximal IMT,
near and far wall, bilateral
Focal calciﬁed plaque
not included
AMI CCA-IMT increment, 0.1 mm;
RR: 2.14 (1.08–4.26)
CHS (16) 5,020 (60) 72.6  5.5 yrs 5 days to 12 yrs
(median, 11 yrs)
CCA and ICA-IMT, mean of
maximal IMT, near and
far wall, bilateral
Plaque included MI, stroke, CV death,
all-cause mortality
Highest tertile: RR: 1.84 (1.54–2.20)
ARIC (17) 12,841 (57) 45–64 yrs Mean follow-up,
15.1 yrs
Mean far wall IMT at 6 sites
(CCA, bulb, ICA, bilateral)
Plaque included MI, CV death IMT $1.0 mm: women: HR: 5.07 (3.08–8.36);
men: 1.85 (1.28–2.69)
CAPS (95) 5,056 (51) 19–90 yrs Mean follow-up,
4.2 yrs
Mean far wall IMT bilaterally at
CCA, carotid BIF, ICA bulb
Not speciﬁed MI, stroke, death RR for 1 SD: RR 1.17 (1.08–1.26) for CCA-IMT;
RR 1.14 (1.05–1.24), for carotid bulb-IMT;
RR 1.09 (1.01–1.18) for ICA-IMT.
MDCS (28) 5,163 (59) 46–68 yrs Median, 7 yrs Mean far wall right distal CCA Plaque included MI, CV death RR for highest tertile: 1.50 (0.81–2.59)
Rotterdam Study (15) 6,389 (61.9) 69.3  9.2 yrs 7–10 yrs Average of maximal CCA-IMT of
near and far wall, bilateral
Not speciﬁed MI RR: 1.95 (1.19–3.19)
LILAC (96) 298 (60) Mean, 79.6 yrs Mean, 1,152 days Average of CCA bilaterally,
near and far wall
Not speciﬁed All-cause mortality For 0.3-mm increase in left IMT, RR: 1.65
(1.08-2.5); right IMT, RR: 3.3 (1.4–7.7)
Three-City Study (52) 5,895 (62.9) 65–85 yrs Median, 5.4 yrs Mean CCA-IMT bilaterally,
near and far wall
Plaque excluded MI, angina, CV death,
revascularization
HR for ﬁfth quintile: 0.8 (0.5–1.2)
IMPROVE (69) 3,703 (52) Median,
64.4 yrs
Median, 36.2
months
Maximal and mean CCA, ICA,
BIF, bilateral
Plaque included MI, SCD, angina, stroke, TIA,
heart failure,
revascularization
HR for 1-SD increase: mean CCA-IMT: 1.33
(1.18–1.50); mean BIF-IMT: 1.28 (1.12–1.47);
mean ICA-IMT: 1.34 (1.18–1.51)
MESA (30) 6,814 (33.3) 45–84 yrs Median, 7.6 yrs Mean of maximal right CCA-IMT,
far wall
Plaque excluded MI, revascularization, SCD,
CV death
HR: 1.17 (0.95–1.45)
The Edinburgh Artery
Study (13)
1,007 (51.7) Mean, 69.4
yrs
12 yrs Maximal far wall CCA-IMT,
bilateral
Not speciﬁed MI, stroke, angina,
claudication
IMT $0.9 mm, OR: 1.59 (1.07–2.37)
Framingham Offspring
Study (84)
2,965 (55.3) 58  10 yrs Average, 7.2 yrs Mean CCA-IMT, or maximal
CCA-IMT, maximal
ICA-IMT, bilateral
Plaque excluded MI, angina, CV death, stroke,
claudication, heart failure
HR for 1-SD mean CCA-IMT: 1.13 (1.02–1.24); HR
for 1-SD maximal CCA-IMT: 1.21 (1.13–1.29);
HR for 1-SD maximal ICA-IMT: 1.21 (1.13–1.29)
Charlottesville
study (42)
727 (45) 16–85 yrs Mean, 4.78 yrs Mean CCA-IMT, bulb-IMT,
ICA-IMT, near and far wall,
bilateral
Plaque included MI, revascularization,
stroke, TIA
OR for highest quartile of carotid bulb
IMT: 5.8 (1.3–26.6)
FATE (97) 1,574 (0) 49.4  9.9 yrs Mean, 7.2 yrs Right CCA-IMT Plaque excluded CV death, revascularization,
MI, angina, stroke
HR: 1.45 (1.15–1.83)
OSACA2 (98) 574 (45.2) 65.3  9.5 yrs Mean, 2.6 yrs Mean maximal CCA-IMT, BIF-IMT,
ICA-IMT, near and far, bilateral
Plaque included MI, CABG, angioplasty,
PAD, stroke
For 1-SD increase, RR: 1.57 (1.11–2.20)
Tromso Study (54) 6,226 (44) 25–84 yrs 6 yrs Mean of near and far wall right
CCA-IMT, and far wall
of the bulb
Plaque included MI Highest IMT quartile, 1.73 (0.98–3.06) in men
and 2.86 (1.07–7.65) in women
CCCC (99) 2,190 (55) $35 yrs Median, 10.5 yrs Maximal CCA-IMT, far wall,
bilateral
Plaque excluded MI, CV death, PCI, CABG RR: 1 SD; 1.38 (1.12–1.70)
APSIS (100) 558 (33) 60  7 yrs Median, 3.0 yrs Maximal left CCA-IMT, far wall Not speciﬁed CV death, MI,
revascularization
IMT >1.02 mm; RR: 0.78 (0.36–1.70) for CV
death or MI; RR: 1.07 (0.56–2.04) for
revascularization
Cournot et al. (101) 2,561 (38.2) 51.6  10.5
yrs
2–10 yrs CCA-IMT, ICA-IMT bilaterally Plaque excluded CV death, MI, angina IMT >0.63 mm; HR: 2.26 (1.35–3.79)
AMI ¼ acute myocardial infarction; APSIS ¼ the Angina Prognosis Study in Stockholm; BIF ¼ bifurcation; CABG ¼ coronary artery bypass graft; CCA ¼ common carotid artery; CCCC ¼ Chin-Shan Community Cardiovascular Cohort Study; CI ¼ conﬁdence interval;
CIMT ¼ cardiac intima-media thickness; CV ¼ cardiovascular; ICA ¼ internal carotid artery; FATE ¼ Fireﬁghters and Their Endothelium study; IMT ¼ intima-media thickness; CV ¼ cardiovascular; HR ¼ hazard ratio; MDCS Malmo ¼ Malmo Die and Cancer Study;
MI ¼ myocardial infarction; NOMAS ¼ Northern Manhattan Study; OR ¼ odds ratio; OSACA2 ¼ Osaka Follow-up Study for Carotid Atherosclerosis; PCI ¼ percutaneous coronary intervention; PAD ¼ peripheral artery disease; RR ¼ relative risk; SCD ¼ sudden cardiac
death; TIA ¼ transient ischemic attack.
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FIGURE 3 Plaque Phenotypes
Images showing variation in plaque morphology. (A) Focal plaque at the far wall of the
carotid bulb with calciﬁcation and acoustic shadowing. Note the entirely normal common
carotid artery intima-media thickness (CCA-IMT). If only CCA-IMT is measured for risk
stratiﬁcation, this patient would be misclassiﬁed as having low cardiovascular risk. (B) This
patient has a focal long homogeneous plaque at the region of the carotid bifurcation, but
also thickening of the near and far wall carotid IMT. (C) Predominantly noncalciﬁed mul-
tiple plaques in the carotid bulb. (D) A large calciﬁed plaque layered along the vessel wall.
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1029ability to image ICA-IMT due to an improvement in
ultrasound imaging techniques and pixel resolution,
found that ICA-IMT is associated with higher relative
risk of incident CVD compared with CCA-IMT (37).
Studies have found greater prediction of stroke by
CCA-IMT (30), whereas ICA-IMT appears to predict
atherosclerotic cardiac events better (16). In the MESA
study (38), age-, race-, and sex-adjusted risk of stroke
per SD increase was 2.5 for CIMT versus 0.4 for
CAC after multivariable adjustment of risk factors
including age, race, sex, ethnicity, smoking, diabetes,
blood pressure, low-density lipoprotein, total choles-
terol, and use of lipid-lowering medication. The in-
ﬂuence of blood pressure on CCA-IMT was indirectly
observed in the RADIANCE (Rating Atherosclerotic
Disease by Imaging with A New CEPP inhibitor) 2 study
in which torcetrapib treatment was associated with an
increase in blood pressure and a nearly signiﬁcant
increase in mean CCA-IMT during study period (p ¼
0.06), without a net yearly rate of change in the
maximal IMT of 12 carotid segments (21), suggesting
that CCA-IMT is more affected by blood pressure than
by atherosclerosis. Besides intimal thickening, CIMT
represents smooth muscle hypertrophy and/or hy-
perplasia, which may be induced by pressure overload
and/or age-related sclerosis (39–41). CIMT is a mea-
surement of the combined thickness of the intima and
the media of the carotid vessel wall. This combined
thickness is chosen because current ultrasound
instruments with the standard transducers have
insufﬁcient axial resolution to discriminate between
the intimal and the medial layers that comprise 20%
and 80% of IMT, respectively (8–10).
QUANTIFYING CIMT
The deﬁnition of an abnormal IMT also differs
between studies. Some use a deﬁnition of an IMT
greater than the 75th percentile (3,42). Others deﬁ-
nitions include an IMT that is >1 SD from the mean or
IMT at the upper quartile or IMT at the upper tertile,
or an absolute IMT value of $0.9 mm or $1 mm
(13,17). An American Society of Echocardiography
consensus statement recommends the use of CIMT
greater than the 75th percentile for age, ethnicity, and
sex as being abnormal (3).
CAROTID PLAQUE. Perhaps the most important dif-
ference in the methodology between studies is how
plaque is treated when assessing CIMT. Different
pathophysiology underlies the development of carotid
plaque and CIMT. Unlike CIMT, carotid plaque repre-
sents predominantly intimal thickening with foam
cells, smooth muscle cells, macrophages, lipid core,
and ﬁbrous cap depending on the stage of plaquedevelopment (43). Not all CIMT studies include plaque
in the CIMT measurements (Table 1). Some studies
speciﬁcally exclude plaque and selectively measure
CIMT in a plaque-free region (44). Others include
plaque when measuring CIMT (17). Figure 3A shows a
patient with a focal nonobstructive carotid plaque
with acoustic shadowing at the far wall of the carotid
bulb. In this case, the CCA-IMT is thin and normal. If
CIMT is measured in the plaque-free CCA, the CIMT
value would be in the normal range, and this patient’s
CV risk as predicted by CIMT would be misclassiﬁed as
being low. This is in contrast to the patient in
Figure 3B, who has a focal long plaque but also has
thickening of the CIMT in the plaque-free area. In this
patient, the CIMT value would be abnormal. Impor-
tantly, near-wall IMT in all segments appears thicker
than far-wall IMT in this patient, but near-wall IMT
was often not measured or reported in several studies
that may have led to underestimation of CVD risk.
CIMT studies have varied widely in how plaques are
deﬁned and how the plaque data are analyzed. The
transition from an increased CIMT to plaque is arbi-
trarily deﬁned, and it is debated whether the transi-
tion from increased carotid IMT to carotid plaque
formation is a continuous process (45) or whether
carotid IMT and plaques are separate phenotypes (40).
Plaque deﬁnition used in some studies may represent
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1030increased IMT. Some studies deﬁne plaque as a focal
thickening of the intima-media >1 mm, protruding
into the lumen, which is at least twice as thick as the
IMT on either side (46). Other studies deﬁne plaques
as carotid IMT >1.2 mm (47). Yet others subjectively
deﬁne plaques as present or absent (48). The Euro-
pean Mannheim consensus deﬁned plaque as a focal
thickening that encroaches into the lumen by 0.5 mm
or by 50% of the surrounding IMT or where IMT is
>1.5 mm (49). Other common criteria for plaque
identiﬁcation are shadowing in wall texture, rough-
ness, and inconsistency in the visualization of struc-
tural boundaries along with bright echogenicity (44).
In studies in which plaques are taken into consid-
eration, the way in which plaques are analyzed dif-
fers. Table 2 lists studies in which carotid plaque was
evaluated as a prognostic predictor of CV events. In
some studies, plaque assessment is qualitative, in
which the presence or absence of plaques was recor-
ded and analyzed categorically as either “yes” or “no”
(50). Others rely on visual assessment of plaque size
and burden, classifying plaque burden as none, mild,
moderate, or severe (51). Other studies are more
quantitative and include detailed analysis of plaque
burden, in which the number of plaques (52), plaque
thickness (53), and plaque area (54–56) are assessed.
Some studies show that “plaque phenotypes” such as
plaque irregularity (57), and plaque calciﬁcation (44)
add to CV risk prediction. Figure 3 illustrates the
variability in plaque size and appearance. Figure 3C
shows a patient with multiple plaques in the carotid
bulb, and Figure 3D shows a patient with a large
calciﬁed layered plaque along the carotid vessel
wall. Thus, plaques differ in their morphology and
composition, and simply categorizing plaque as “yes”
and “no” clearly fails to capture plaque complexity
and its implications for CV risk.
New technology may aid in the ultrasound charac-
terization of complex plaques. Computerized algo-
rithms based on gray-scale pixel analysis have been
developed for texture analysis of plaques. Pixel-
distribution analysis further provides a quantitative
method for assessing plaque composition (58). These
tools have been validated against tissue characteristics
of endarterectomy specimens (58,59) as well as clinical
endpoints. Echolucent carotid plaques and plaques
with surface irregularity are associated with a higher
risk of future ischemic stroke and a low level of
high-density lipoprotein cholesterol level (60).
Furthermore, plaque lucency is more reproducible
than plaque thickness measurement (61). Three-
dimensional measurement of plaque volume (62) and
vessel volume (63) has shown promise in determining
regression of atherosclerosis and is being testedfor CV risk prediction (64). Plaque vascularity, which
relates to activity of atherosclerosis, can be assessed
with the use of ultrasound contrast agents, but its
use has not been tested in a prognostic setting (65). Coli
et al. (66) demonstrated that quantitative evaluation of
vasa vasorum on pathology correlated with qualitative
assessment of plaque vascularity by ultrasound.
Additionally, increased plaque vascularity by ultra-
sound correlated well with B-mode echolucency,
which is a sign of a vulnerable plaque.
PREDICTIVE VALUE OF IMT VERSUS PLAQUE IN
POPULATION-BASED STUDIES IN PREDICTING
FUTURE MI. Given that plaque formation is a mani-
festation of atherosclerosis, it is not surprising that the
presence of plaques predicts future CV events. Ameta-
analysis of 11 population-based studies including
54,336 patients showed that carotid plaque, when
compared with CIMT (inclusive of CCA, bulb, and/or
ICA depending on the study), had a signiﬁcantly higher
diagnostic accuracy for the prediction of futureMI (67).
After adjusting for Framingham risk factors, the rela-
tive diagnostic odds ratio comparing plaques and CIMT
assessment was 1.35, suggesting that plaque assess-
ment was 35% better than CIMT in predicting future
cardiac events. The speciﬁcity of event prediction was
also higher with carotid plaque. The 10-year event
rates of MI after negative results were lower with ca-
rotid plaques compared with a normal CIMT.
These studies suggest that varying results among
studies are likely related to methodology and that
CCA-IMT measurement at sites not containing pla-
que, versus IMT measurement in the carotid bulb
and ICA, inclusive of plaque, if present, represent 2
separate phenotypes. Measurement of carotid plaque
alone was more predictive of CV events than either
IMT phenotype in a meta-analysis (67,68). In addi-
tion, assessment of CIMT at multiple angles evaluates
the asymmetrical nature of atherosclerosis better
than measurement at a single angle only.
Analyses of individual studies also suggest that
plaque is more effective than CIMT in predicting
future CV events. Mean CIMT of all segments when
added to TRFs and plaque signiﬁcantly increased
CHD risk prediction in men but not in women in the
ARIC study (50). The ARIC study (Table 1) included
13,145 healthy subjects (7,463 women) between 45
and 64 years of age at the time of the baseline study
visit (50). Over a mean follow-up of 15.2 years, there
were 1,822 CV events that included MI, death, and
revascularization. The model that performed the best
included TRFs plus CIMT plus plaque. When the TRFs
plus CIMT plus plaque model was compared with the
TRFs-only model, the NRI was 9.9% in the overall
sample (8.9% in men and 9.8% in women) and
TABLE 2 Carotid Plaque as Prognostic Indicator of Cardiovascular Events
Study (Ref. #)
Sample Size,
No. (% Women)
Age of
Subjects, yrs Follow-Up Deﬁnition of Plaque Endpoints Plaque RR (95% CI)
Tromso Study (54) 6,226 (44) 25–84 6 yrs Localized protrusion of the vessel wall into the
lumen
MI Highest plaque area tertile, RR: 1.56 (1.04–2.36) in
men and RR: 3.95 (2.16–7.19) in women
APSIS (100) 558 (33) 60  7 Median, 3.0 yrs Distinct area with IMT more than twice that
of neighboring sites
CV death, MI Presence of plaque, RR: 1.83 (0.96–3.51)
KIHD (25) 1,288 (0) 42–60 1 month to 2.5 yrs Area with mineralization or focal protrusion into
the lumen, measured at the carotid bulb
MI Small plaque, RR: 4.15 (1.51–11.47); large plaque,
6.71 (1.33–33.91)
Rotterdam Study (15) 6,389 (61.9) 69.3  9.2 7–10 yrs Focal widening relative to adjacent segments
with protrusion into the lumen
MI HR for severe plaque: 1.83 (1.27–2.62)
ARIC (50) 13,145 (57) 54.0  5.8 Mean, 15.1 yrs Plaque deﬁned as meeting 2 of 3 criteria:
1) CIMT >1.5 mm; 2) protrusion into the
lumen; and 3) abnormal wall texture
MI, CV death, revascularization HR varied depending on risk factors. Model with
plaque and CIMT improved area under the
curve from 0.742 to 0.755
MDCS (28) 5,163 (59) 46–68 Median, 7 yrs Focal IMT >1.2 mm MI, CV death RR for presence of plaque: 1.81 (1.14–2.87)
Cournot et al. (101) 2,561 (38.2) 51.6  10.5 2–10 yrs Focal protrusion into the vessel lumen CV death, MI, angina RR for the presence of plaque 2.81 (1.84–4.29)
CCCC (99) 2,190 (55) $35 Median, 10.5 yrs Graded based on stenosis. Grade 1, <30%;
grade 2, 30%–49%; grade 3, 50%–99%;
grade 4, 100%
MI, CV death, PCI, CABG, stroke For 1-point increase in plaque score,
RR: 1.11 (0.99–1.24)
NOMAS (44) 1,118 (59) 68  8 Mean 2.7 years >50% increase in thickness compared with
neighboring wall. Characterized as noncalciﬁed
plaques and calciﬁed plaques
Stroke, MI, CV death Calciﬁed plaque, RR: 2.4 (1.0–5.8); noncalciﬁed
plaques, RR: 1.5 (0.7–3.4)
Three-City Study (52) 5,895 (62.9) 65–85 Median, 5.4 yrs Wall thickening $50% compared with surrounding
vessel wall
MI, angina, CV death,
revascularization
Any plaques, HR: 1.5 (1.0–2.2); plaques at $2 sites,
HR: 2.2 (1.6–3.1)
CHS (16) 5,020 (60) 72.6  5.5 5 days to 12 years
(median, 11 yrs)
High-risk plaques were deﬁned as markedly
irregular, ulcerated surface, hypodense,
heterogeneous plaques >50% of total plaque
volume
MI, stroke, CV death and
all-cause mortality
High-risk plaque, RR: 1.38 (1.14–1.67);
RR for mortality: 1.23 (1.04–1.44)
Framingham Offspring
Study (84)
2,965 (55.3) 58  10 Average, 7.2 yrs ICA-IMT $1.5 mm MI, angina, CV death, stroke,
claudication, heart failure
Presence of plaque, HR: 1.91 (1.49–2.47)
Prati et al. (57) 1,348 (53) 18–99 Average, 12 yrs Focal structure encroaching into the lumen
with maximal thickness >1.5 mm
Vascular death, stroke Event incidence for group with high total plaque
score: 50–75 yrs, 2.9% (1.1–7.5);
>75 yrs, 9.6% (5.6–17.0)
Stork et al. (102) 403 (0) 77.7  3.5 48 months Focal widening with protrusion into the lumen CV death RR: 1.16 (1.03–1.31)
Xie et al. (103) 3,258 (59) 38–79 5 yrs IMT $1.5 mm MI, CVA CCA plaque, RR: 1.90 (1.15–3.13); BIF plaque,
RR: 1.26 (0.86–1.83)
CAFES-CAVE (88) 10,000 (30.5) 53.2  6.3 10 yrs Class I, normal; class II, IMT >1 mm; class III,
plaque deﬁned as IMT 1 mm with irregular
increased echogenicity; class IV, stenotic
plaque with stenosis >50%
MI, CV death, revascularization Event rate by class: class I, 0.1%; class II, 8.6%;
class III, 39.28%; class IV, 81.5%
MESA (85) 6,562 (52.6) 61.1  10.2 Mean, 7.8 yrs 0%, 1%–24% narrowing, 25%–49% narrowing,
and >50% narrowing (deﬁned as peak
systolic velocities $125 cm/s)
CHD (MI, CV death, angina,
revascularization), stroke,
death after stroke
Plaque >0%, HR: 1.67 (1.33–2.10); plaque 25%,
HR: 1.67 (1.30–2.13)
CAFES-CAVE ¼ carotid-femoral morphology and cardiovascular events; CHD ¼ coronary heart disease; CVA ¼ cerebrovascular accident; other abbreviations as in Table 1.
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103221.7% in the intermediate-risk groups (16.4% in men
and 25.4% in women). None of the subjects were
reclassiﬁed from the high-risk group to the low-risk
group or vice versa. In this study, the ICA IMT could
not be measured in more than one-half of the cases,
and plaques were classiﬁed categorically as “yes” or
“no.” Despite these limitations, this study showed
that when plaque data are added to any level of IMT
(at less than the 25th percentile, 25th to 75th per-
centiles, or higher than the 75th percentile), there was
an added improvement in risk CHD prediction in both
men and women. It should be noted that, in this
study, plaque data were obtained from the near and
far wall of all carotid segments, whereas IMT
data were obtained only from the far wall of all seg-
ments and was inclusive of plaque in the far wall.
In this study, adding plaque and CIMT data best
improved risk prediction in men and women in the
intermediate-risk group; however, plaque presence
had a more profound effect on improving risk pre-
diction in women than in men. It may be that CIMT
(of the far wall of all carotid segments) in men had
already included plaques, which are more prevalent
in men, whereas additional assessment of plaque in
the near wall in women, who might have small plaque
burden overall, improved assessment of atheroscle-
rosis that might not have been represented by CIMT
of the far wall alone.
The Three-City Study evaluated older individuals
65 to 85 years of age over a median follow-up period
of 5.4 years. Among 5,895 adults with no history of
coronary artery disease, the presence of carotid pla-
que, but not CCA-IMT measured at a plaque-free site,
was found to be an independent predictor of a ﬁrst
cardiac event (52). On multivariate analysis, carotid
plaque at 1 site was associated with a hazard ratio
(HR) of 1.5 (95% conﬁdence interval: 1.0 to 2.2), and
the presence of plaques at $2 sites was associated
with an HR of 2.2 (95% conﬁdence interval: 1.6 to 3.1).
Adding carotid plaques to conventional risk factors
signiﬁcantly improved cardiac risk prediction, with
an NRI of 13.7%. This study highlights the methodo-
logical issue of differentiation of CIMT at plaque-free
sites versus IMT inclusive of plaque.
The Tromso Study evaluated total plaque area in
6,226 individuals 25 to 84 years of age with no history
of MI. Plaque burden was separated into tertiles. After
a 6-year follow-up, MI occurred in 6.6% of men and
3.0% of women. Men in the highest tertile of plaque
had a 56% higher risk of MI compared with those with
no plaque. For women, those in the highest tertile
had a 3.9-fold higher risk. This study also analyzed
carotid IMT and found that IMT did have predictive
power, but when carotid bulb IMT was excluded fromthe analyses, IMT did not predict MI in either sex (54).
Because plaque develops in the carotid bulb, pre-
sumably the loss of predictive power was due to the
exclusion of plaque from the analysis. Extending the
analysis to 10 years, the Tromso group found that
plaque, but not IMT, was predictive of ﬁrst-ever
ischemic stroke. The multivariable-adjusted HR in
the highest quartile of plaque area versus no plaque
was 1.73 (p ¼ 0.004) in men and 1.62 (p ¼ 0.03) in
women. There was no difference in stroke risk across
quartiles of IMT in multivariate analysis (55).
The investigators for the Three-City Study showed
that plaque but not CIMT added to CVD risk predic-
tion over TRFs (52), and the HRs for incident CVD
events increased as the number of sites with plaque
increased. Similar ﬁndings were observed in the
IMPROVE (Carotid Intima Media Thickness [IMT] and
IMT-Progression as Predictors of Vascular Events in a
High Risk European Population) study (69), where the
mean of maximum measurements of all carotid ICA
IMT segments performed signiﬁcantly better than
CCA far-wall mean IMT in reclassiﬁcation of coronary
or CV events in models adjusted for risk factors. In
this study, the presence of at least 1 plaque, deﬁned as
maximal IMT >1.5 mm, performed signiﬁcantly better
than mean IMT only when the latter was measured in
plaque-free areas; otherwise, the predictive value of
the plaque presence alone was always signiﬁcantly
worse. This is likely because, in this study, mean or
maximal IMT was inclusive of plaque in all segments
and was representative of combined CIMT and plaque.
These studies suggest that carotid plaque has pre-
dictive power for incident atherosclerotic heart dis-
ease. Plaques tend to form at the carotid bulb and at the
ICA. This may explain why IMT measurements from
these segments are good predictors of CV events,
whereas IMTmeasurements from the CCA alone or IMT
measurements that speciﬁcally exclude plaque are less
predictive of atherosclerotic cardiac disease. Because
increased CCA-IMT is associated with an increased
stroke risk, combined assessment of FRS, IMT, and
plaque may enhance prediction of total CVD (70).
ASSOCIATION OF CIMT AND PLAQUE
WITH RISK FACTORS
Another clue to the link between CIMT and plaque in
CVD risk prediction comes from their association with
risk factors. The British Regional Heart Study, in which
CCA far-wall IMT was measured along with bulb IMT
and plaque, found that CCA-IMT and bulb IMT were
correlated with each other but showed differing pat-
terns of association with risk factors and prevalent
atherosclerotic disease (71). CCA-IMT was strongly
FIGURE 4 Carotid Plaque Burden Quantitation
Three-dimensional plaque data acquired using a VL13-5 probe with a Philips iU22 ultrasound
scanner (Philips Healthcare, Andover, Massachusetts). The VL13-5 is a high-resolution linear
array with 192 elements that mechanically acquires a series of conventional images covering
the whole carotid bifurcation with a sweep in w3 to 4 s. These images are automatically
combined to create a 4  2.5  2.5-cm “block” of voxels. XRES is a post-processing
technique that removes speckle from the image, yielding an image with better borders and
less clutter (noise) in the image. A series of image slices in transverse section are shown by
the thumbnails (middle). Each image slice is analyzed with semiautomated software to
quantify plaque area, percentage of stenosis, and plaque volume. Plaque areas from all
images in the entire image sequence are summed as “plaque burden.” An image of the
common carotid artery in one of the slices is shown. The yellow border represents the
lumen/intima border; the red border represents the media-adventitia border. The blue
border represents the boundary of the plaque. The graph at the bottom of the image de-
picts the plaque (yellow line) area as a percentage of vessel area (percentage of stenosis),
which is maximal in the image slice shown. Image courtesy of Philips Healthcare.
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1033associated with risk factors for stroke and with preva-
lent stroke, whereas bulb IMT and plaque were more
directly associated with ischemic heart disease risk
factors and prevalent ischemic heart disease. IMT is
strongly inﬂuenced by genetic determinants, but pla-
que appears to be determined by common CHD risk
factors such as age, sex, hypertension, diabetes
mellitus, hypercholesterolemia, amount of nicotine
consumed, factor VIII, and von Willebrand factor but
not genetic inheritance (72). Plaques also correlate
with other measures of atherosclerotic vascular dis-
ease, such as aortic stiffness, whereas no such associ-
ation was found for CIMT (73). In particular, echogenic
plaques are associated with increased arterial stiffness
(74). In multivariable linear regression, traditional
coronary risk factors explain only 15% to 17% of IMT, as
assessed by the R2 statistic (75) but account for 52% of
the carotid total plaque area (76).
Besides association with TRFs and a predictive role
for CVD risk, an important question in the develop-
ment of a new biomarker is its clinical utility (i.e.,
does the novel risk marker change predicted risk
sufﬁciently to change recommended therapy). Single-
center studies suggest such imaging results lead to
changes in physician prescribing pattern (77),
although larger studies are needed in this area.
Whether the use of CIMT and plaque assessment will
improve clinical outcomes in a randomized clinical
trial remains to be tested and may never be per-
formed, given the costs involved. Cost-effectiveness
analyses have suggested justiﬁcation of the addi-
tional costs of testing with CIMT and plaque assess-
ment and treatment (78).
3-DIMENSIONAL PLAQUE ASSESSMENT FOR
CORONARY ARTERY DISEASE AND PLAQUE
PROGRESSION AND REGRESSION. The advent of
3-dimensional (3D) ultrasound allows more accurate
quantiﬁcation of plaque burden. Plaques are outlined
on cross-sectional images, and plaque areas are
summed up to obtain the total plaque burden (64)
(Figure 4). An advantage of performing 3D measure-
ments is the large dynamic scale range of plaque vol-
ume or plaque area that enables the assessment of
progression or regression of disease in individual
subjects. With CIMT measurements, most measure-
ments fall in the submillimeter range. The annual
change of CIMT value is roughly 0.01 to 0.04 mm per
year in health (26) and disease (79,80), which is lower
than the current-generation ultrasound pixel resolu-
tion of 0.1 to 0.2 mm, making it very difﬁcult to follow
CIMT change in individual subjects in the short term. A
meta-analysis that included 16 studies with 36,984
participants in whom CIMT was assessed at least twice
showed that even though the CIMT value itself at bothtime points was associated with future CV risk, there
was no association between the progression of CIMT
and future CV risk (81). Compared with CIMT, total
plaque area has a dynamic range of 5 to 500 mm2, w2
orders of magnitude higher than the range for CIMT
measurements (82). The average change in total pla-
que area is 10 mm2 per year, so progression or regres-
sion of disease can be easily measured in months (56),
allowing assessment of the effect of therapy with a
short follow-up. As an example, using 3D plaque vol-
ume assessment, 1 group has been able to show large
effects of therapy on atherosclerosis within 3 months
with a sample size of onlyw20 patients per group (62).
Carotid vessel wall volume, as assessed using carotid
3D ultrasound, is another parameter that has a good
dynamic range. This was used successfully in a dietary
intervention trial to evaluate the effect of different
diets on atherosclerosis (63). 3D plaque volume was
also shown to have a high negative predictive value to
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1034exclude signiﬁcant coronary artery disease compared
with 2-dimensional assessment of plaque by indi-
cating its potential role as a clinical screening tool to
help identify patients who are at low risk of signiﬁcant
coronary artery disease (83).
3D PLAQUE CHARACTERISTICS. Apart from improving
quantiﬁcation of plaque burden, contemporary studies
have also started to focus on better characterization of
plaque morphology. A plaque scoring system was
developed that incorporates stenosis degree, plaque
surface irregularity, echolucency, and plaque texture.
Individuals in the San Daniele study who had high
plaque scores, which correspond to plaques that are
stenotic, with high echogenicity, complex heteroge-
neous echocardiographic pattern, and irregular pla-
que contours, had a higher risk of the development
of CV events (57). This plaque score was shown to
signiﬁcantly increase the predictive power of using
TRFs alone.
NRI OF CAC VERSUS IMT VERSUS PLAQUE
IN CVD RISK RECLASSIFICATION
Studies that have compared CIMT and CAC scores
head to head in asymptomatic individuals have in
general found that IMT and plaque assessment is
more sensitive to detect atherosclerosis than the CAC
score (4,64). Unlike the CAC score cutoff values
of <100, 100 to 400, and >400 (64), the abnormal IMT
value is not as deﬁned. IMT is a normal structure,
whereas CAC is pathological. Varying measures have
been used to deﬁne IMT from single or multiple sites
from the near or far wall including, maximal IMT and
mean IMT. IMT cutoff that is 75th percentile for age,
race, and sex is the most widely used deﬁnition,
although quintiles, SD, and upper and lower quartiles
or tertiles are also used. Hence, what is an abnormal
IMT is more difﬁcult to deﬁne than the CAC score. In a
recent study, Polak et al. (84) evaluated the 2,965-
member Framingham Offspring Study cohort for an
average follow-up of 7.2 years. The NRI increased
signiﬁcantly after the addition of IMT of the ICA
(7.6%) but not IMT of the CCA (0.0%). Because pla-
ques form in the ICA, this was analyzed speciﬁcally
and the presence of plaque, which was deﬁned as IMT
of the ICA >1.5 mm, was associated with an NRI of
7.3%. The analysis of the MESA study data by Polak
et al. (85) also showed an NRI of 7% for the mean of
maximum measurements of ICA IMT added to TRFs.
IMT and CAC do not appear comparable for risk
prediction. The annual NRI and clinical NRI of plaque
and CIMT combined with the FRS were 9.9% and
21.7%, respectively, in the ARIC study. CAC studies, on
the other hand, have shownNRIs of 21.7% and 30.6% atCAC cutoff points of 100 and 400, respectively (86). CV
event rates of 1.431% per year occurred during pro-
spective follow-up of patients who had a CAC score of
>100 in the MESA (38), in which adjustment for TRFs
showed that each 1-SD increase in log-transformed
CAC was associated with an HR of CV events of 2.1,
whereas for CIMT, it was 1.3; however, CIMT predicted
stroke risk modestly better in this study (HR: 2.1 for
CIMT vs. 1.2 for CAC) Plaque was not included in this
CIMT analysis. A more comparable HR for incident
CVD was found in the Pittsburgh Field Center of the
Cardiovascular Health Study for CIMT (HR: 2.3) and
CAC score (HR: 2.1) in subjects with a mean age of 80
years (87). This suggests that the mere presence of 1 or
more 1.5-mm plaque does not comparably represent
atherosclerotic burden as a CAC score of 100 or 400. A
much larger plaque burden as a nonhemodynamically
obstructive plaque or an obstructive plaque was asso-
ciated with CV event rates of 39% and 81%, respec-
tively, at 10 years (88). These event rates are
comparable to those predicted by CAC scores of 400 in
the MESA (38) and St. Francis Heart Study (89). IMT
and plaque assessment as used at present is a 2-
dimensional technique, whereas CAC is a 3D tech-
nique. 3D ultrasound assessment of plaque area or
volume was found to correlate more strongly with CAC
score (chi-square: 450) than CIMT (chi-square: 24) and
would be more reliable in CV risk prediction (64).
FOLLOW-UP IMT MEASUREMENT
The theoretical axial resolution of an ultrasound
system varies from 0.08 to 0.11 mm for 12-MHz and 7-
MHz transducer frequency, respectively. A small
change in IMT cannot be measured in individuals (on
the order of 0.01 to 0.1 mm) in clinically meaningful
timeframes, especially taking into consideration
reader error and patient factors leading to variability.
Follow-up measurement of IMT is only recommended
in large research studies in which standardized IMT
protocols including multiple angles, anatomic land-
marks, and automated edge detection software tech-
nology are used to assess IMT progression or
regression on serial measurements in a large dataset.
Duplicate measurement of IMT at baseline and
follow-up reduces this error.
UTILITY OF IMT IN YOUTHS
CIMT provides a measurable reliable marker of the
atherosclerotic disease process in the young, a group in
whomvascular eventswill not occur for decades and in
whom plaque formation or calciﬁcation has not
occurred (90). Mean CCA-IMT, bulb, and ICA-IMTwere
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1035increased in children with type 1 diabetes mellitus and
obese children compared with lean children (91).
RELATIVE MERITS/DEMERITS OF CIMT/PLAQUE
MEASUREMENT VERSUS CAC IN ASSESSING CV RISK
IN ASYMPTOMATIC INDIVIDUALS. One of the limi-
tations of ultrasound is image quality, which depends
highly on the sonographer‘s ability to provide a
comprehensive scan using appropriate standardized
angles, and the like. CAC measurement, on the other
hand, is fairly automated and easy to perform. Patient
body habitus can similarly have a greater impact on
ultrasound images relative to other imaging modal-
ities. Finally, because CIMT measurements are
exacting, small changes (which may occur with minor
changes in the angle of imaging) can have an impact
on the measured value and hence the interpretation
of the test. The advantages of ultrasound scanning
are several: there are no major side effects to the test
(minimal heating of tissue is possible), no radiation is
involved, scans can be done on portable devices, and
the overall acquisition time is fast, which offers the
possibility of higher throughput, lower cost, and
relative safety.
ASSESSMENT OF IMT AND PLAQUE
IN CLINICAL PRACTICE
Previous studies required ofﬂine measurements of
IMT using calipers or edge detection software in a
core laboratory, making IMT measurement cumber-
some and time-consuming. Recent advances in-
cluding the use of dedicated IMT ultrasound systems
(92) and simpliﬁcation of IMT protocols have made
IMT measurement practical (3). Measurement of CCA-
IMT has become automated and is standardized and
reproducible if a careful protocol is followed. Our own
experience shows good interobserver agreement in
IMT and plaque assessment when nonsonographer
physician residents are trained in IMT acquisition on
more recent generation ultrasound systems that
perform online edge detection of IMT (93). On the
other hand, assessment of plaque burden is more
qualitative at present, and reproducibility of carotid
plaque quantiﬁcation has not been well studied. Use
of anatomic landmarks, similar angles at baseline and
follow up as well as development of technology thattracks imaging angle and annotates it on the screen
may be used to more precisely assess IMT progression
or regression on serial measurements (93).
FUTURE DEVELOPMENT
It appears that plaque detection by ultrasound imag-
ing may not require the intensive training that is
required for measurement of CIMT and that plaque
screening may be more easily accomplished in the
outpatient setting. Plaque reproducibility needs to be
deﬁned in large multicenter studies. Abnormal cutoff
values for plaque presence and size or volume
adjusted for age, race, and sex and plaque measure-
ment variability need to be deﬁned. Effect of plaque
characteristics on outcome is not well deﬁned in
large studies, although preliminary data suggest the
utility of contrast imaging in assessing plaque neo-
vascularization (94). Considerable research is needed
to illuminate the conditions and/or cohorts where
one methodology may be superior to the other.
Current methodologies are relatively silent on plaque
vulnerability and triggering conditions, limiting
attainable improvements in risk classiﬁcation.
CONCLUSIONS
The controversy surrounding the usefulness of CIMT
measurement in risk stratiﬁcation appears to result
from the lack of uniform methodology used in CIMT
studies. Measurements of IMT at the carotid bulb and
at the ICA are more useful than CCA-IMT, both for risk
classiﬁcation and risk prediction, likely because
intimal thickening and plaques form at the bulb and at
the ICA. Assessment of plaque burden is a better
measure of atherosclerosis and CV risk than is a simple
assessment of the presence or absence of plaques.
Combined CIMT and plaque assessment appear better
than either measure alone. 3D plaque volume corre-
lates with CAC score. In the future, plaque progression
and regression assessed by 3D ultrasoundmay serve as
a powerful tool to evaluate the effect of CV therapy.
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